Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 1 2014
Print

Financial Report: Elan



Published July 24, 2013
Elan
 
2Q Revenues:
$56.3 million ($0.2 million 2Q12)

2Q Earnings: $2.3 billion (loss of $28.5 million 2Q12)

YTD Revenues: $56.5 million (n/a)

YTD Earnings: $2.4 billion (loss of $60.3 million YTD12)

Comments: Results included $2.5 billion income from the transfer of Tysabri to partner Biogen. Under the Tysabri transaction, Elan received an upfront payment of $3.3 billion and will continue to receive royalties on Tysabri in-market sales. Earnings in the quarter includes a net loss from continuing operations of $251.8 million ($90.0 million 2Q12) and net income from discontinued operations of $2.5 billion. YTD earnings includes a net loss from continuing operations of $324.6 million ($164.7 million YTD12), and net income from discontinued operations of $2.7 billion ($104.4 million in YTD12) related to the Tysabri, Prothena and EDT businesses. According to a board announcement in June, Elan is in the process of exploring the sale of the company.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On